Dr Oliver M Dovey | Head of Gene Editing, Cellular Operations

Dovey, Oliver M

Oliver leads the Gene Editing, Cellular Operations group. Having started his career as a research assistant at the Sanger Institute, with the Microarray Facility (lead by Cordelia Langford) and the Mouse Genetics team (lead by Prof. Allan Bradley), he obtained his PhD from the University of Leicester with Prof. Shaun Cowley studying the molecular and physiological effects of chromatin modifying proteins through the use of engineered Stem Cells and murine models. From here he returned to the Sanger Institute to study Haematological Cancer Genetics with Prof. George Vassiliou. Using bespoke engineered murine models, reverse (CRISPR-ko) and forward (transposon mediated insertional mutagenesis) screening platforms he worked to determine the physiological, molecular, pharmacological and genetic interactions (as well as sensitivities) of Acute Myeloid Leukaemia. He took up post as Head of Cellular Operations Gene Editing Team (formerly High Throughput Gene Editing) in 2018 and his team perform experiments which require Genome Engineering and develop an array of Gene Editing tools and platforms for the Institute.

Publications

  • UTX-mediated enhancer and chromatin remodeling suppresses myeloid leukemogenesis through noncatalytic inverse regulation of ETS and GATA programs.

    Gozdecka M, Meduri E, Mazan M, Tzelepis K, Dudek M et al.

    Nature genetics 2018;50;6;883-894

  • Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes.

    Mueller S, Engleitner T, Maresch R, Zukowska M, Lange S et al.

    Nature 2018;554;7690;62-68

  • Molecular synergy underlies the co-occurrence patterns and phenotype of NPM1-mutant acute myeloid leukemia.

    Dovey OM, Cooper JL, Mupo A, Grove CS, Lynn C et al.

    Blood 2017;130;17;1911-1922

  • A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia.

    Tzelepis K, Koike-Yusa H, De Braekeleer E, Li Y, Metzakopian E et al.

    Cell reports 2016;17;4;1193-1205

  • Histone deacetylase 1 (HDAC1), but not HDAC2, controls embryonic stem cell differentiation.

    Dovey OM, Foster CT and Cowley SM

    Proceedings of the National Academy of Sciences of the United States of America 2010;107;18;8242-7

  • The long non-coding RNA HOXB-AS3 regulates ribosomal RNA transcription in NPM1-mutated acute myeloid leukemia.

    Papaioannou D, Petri A, Dovey OM, Terreri S, Wang E et al.

    Nature communications 2019;10;1;5351

  • SOCS2 is part of a highly prognostic 4-gene signature in AML and promotes disease aggressiveness.

    Nguyen CH, Glüxam T, Schlerka A, Bauer K, Grandits AM et al.

    Scientific reports 2019;9;1;9139

  • UTX-mediated enhancer and chromatin remodeling suppresses myeloid leukemogenesis through noncatalytic inverse regulation of ETS and GATA programs.

    Gozdecka M, Meduri E, Mazan M, Tzelepis K, Dudek M et al.

    Nature genetics 2018;50;6;883-894

  • Mutant calreticulin knockin mice develop thrombocytosis and myelofibrosis without a stem cell self-renewal advantage.

    Li J, Prins D, Park HJ, Grinfeld J, Gonzalez-Arias C et al.

    Blood 2018;131;6;649-661

  • Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes.

    Mueller S, Engleitner T, Maresch R, Zukowska M, Lange S et al.

    Nature 2018;554;7690;62-68

  • Molecular synergy underlies the co-occurrence patterns and phenotype of NPM1-mutant acute myeloid leukemia.

    Dovey OM, Cooper JL, Mupo A, Grove CS, Lynn C et al.

    Blood 2017;130;17;1911-1922

  • Preventing chemotherapy-induced myelosuppression by repurposing the FLT3 inhibitor quizartinib.

    Taylor SJ, Duyvestyn JM, Dagger SA, Dishington EJ, Rinaldi CA et al.

    Science translational medicine 2017;9;402

  • A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia.

    Tzelepis K, Koike-Yusa H, De Braekeleer E, Li Y, Metzakopian E et al.

    Cell reports 2016;17;4;1193-1205

  • Promiscuous targeting of bromodomains by bromosporine identifies BET proteins as master regulators of primary transcription response in leukemia.

    Picaud S, Leonards K, Lambert JP, Dovey O, Wells C et al.

    Science advances 2016;2;10;e1600760

  • Identification of a germline F692L drug resistance variant in cis with Flt3-ITD in knock-in mice.

    Dovey OM, Chen B, Mupo A, Friedrich M, Grove CS et al.

    Haematologica 2016

  • Histone deacetylase (HDAC) 1 and 2 are essential for accurate cell division and the pluripotency of embryonic stem cells.

    Jamaladdin S, Kelly RD, O'Regan L, Dovey OM, Hodson GE et al.

    Proceedings of the National Academy of Sciences of the United States of America 2014;111;27;9840-5

  • A powerful molecular synergy between mutant Nucleophosmin and Flt3-ITD drives acute myeloid leukemia in mice.

    Mupo A, Celani L, Dovey O, Cooper JL, Grove C et al.

    Leukemia 2013;27;9;1917-20

  • Histone deacetylase 1 and 2 are essential for normal T-cell development and genomic stability in mice.

    Dovey OM, Foster CT, Conte N, Edwards SA, Edwards JM et al.

    Blood 2013;121;8;1335-44

  • Lysine-specific demethylase 1 regulates the embryonic transcriptome and CoREST stability.

    Foster CT, Dovey OM, Lezina L, Luo JL, Gant TW et al.

    Molecular and cellular biology 2010;30;20;4851-63

  • Emphasizing the positive: A role for histone deacetylases in transcriptional activation.

    Dovey OM, Foster CT and Cowley SM

    Cell cycle (Georgetown, Tex.) 2010;9;14;2700-1

  • Histone deacetylase 1 (HDAC1), but not HDAC2, controls embryonic stem cell differentiation.

    Dovey OM, Foster CT and Cowley SM

    Proceedings of the National Academy of Sciences of the United States of America 2010;107;18;8242-7

  • Loss of Rassf1a cooperates with Apc(Min) to accelerate intestinal tumourigenesis.

    van der Weyden L, Arends MJ, Dovey OM, Harrison HL, Lefebvre G et al.

    Oncogene 2008;27;32;4503-8

  • Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project.

    ENCODE Project Consortium, Birney E, Stamatoyannopoulos JA, Dutta A, Guigó R et al.

    Nature 2007;447;7146;799-816

  • Butyrate mediates decrease of histone acetylation centered on transcription start sites and down-regulation of associated genes.

    Rada-Iglesias A, Enroth S, Ameur A, Koch CM, Clelland GK et al.

    Genome research 2007;17;6;708-19

  • The landscape of histone modifications across 1% of the human genome in five human cell lines.

    Koch CM, Andrews RM, Flicek P, Dillon SC, Karaöz U et al.

    Genome research 2007;17;6;691-707

  • Accurate and reliable high-throughput detection of copy number variation in the human genome.

    Fiegler H, Redon R, Andrews D, Scott C, Andrews R et al.

    Genome research 2006;16;12;1566-74

  • Array CGH profiling of favourable histology Wilms tumours reveals novel gains and losses associated with relapse.

    Natrajan R, Williams RD, Hing SN, Mackay A, Reis-Filho JS et al.

    The Journal of pathology 2006;210;1;49-58

  • The DNA sequence and biological annotation of human chromosome 1.

    Gregory SG, Barlow KF, McLay KE, Kaul R, Swarbreck D et al.

    Nature 2006;441;7091;315-21

  • Binding sites for metabolic disease related transcription factors inferred at base pair resolution by chromatin immunoprecipitation and genomic microarrays.

    Rada-Iglesias A, Wallerman O, Koch C, Ameur A, Enroth S et al.

    Human molecular genetics 2005;14;22;3435-47

Dovey, Oliver M
Oliver's Timeline
2019

Head of Gene Editing, Cellular Operations

2018

Head of High Throughput Gene Editing, Cellular Operations

2015

Staff Scientist in the Haematoligical Cancer Genetics Group, Sanger Institute

2011

Joined Haematoligical Cancer Genetics Group, Sanger Institute as a Post Doctoral Fellow.

Awarded PhD from the University of Leicester

2007

Joined the Cowley Lab, Department of Biochemistry, University of Leicester.

2005

Research Assistant, Bradley Lab, Sanger Institute.

2002

Research Assistant, Microarray Facility, Sanger Institute.